Eriodictyol controls a key enzyme to activate mitochondrial cleaning that reduces inflammation for treating bone loss

Eriodictyol (ERI) is identified as a natural inhibitor of lactate dehydrogenase B (LDHB) that may protect against bone loss.

• Imbalance in bone homeostasis can lead to excessive bone resorption and loss of bone mass.
• Eriodictyol may inhibit the activation of the NLRP3 inflammasome, a key player in inflammation.
• The protective effect of ERI against bone loss is associated with enhanced mitophagy, which helps maintain healthy cellular function.
• Further research is needed to fully elucidate ERI's role in bone health.

Simplified